Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Amylyx Pharmaceuticals

Biogen

bluebird bio

Gilead Sciences

TG Therapeutics

If readouts on clinical trials can impact the stocks of pharma companies, the Food and Drug Administration (FDA) decisions on whether or not specific drugs are approved can affect not only the stock price but also a company's future.

5 Key FDA Decisions Could Affect Drug Stocks

Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.

Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC

AbbVie

Vertex Pharmaceuticals

All three are near 52-week highs, but for how long?

3 Soaring Pharma Stocks -- Can They Keep Climbing?

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #AACR--Neoadjuvant Opdivo with Chemo Significantly Improves Event-Free Survival in Patients with Resectable NSCLC in Phase 3 CheckMate -816 Trial

Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Foundation Honors Diversity & Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences

Bristol Myers Squibb Foundation Honors Diversity and Health Equity Leader By Naming Diversity in Clinical Trials Training Program After Him; Welcomes Gilead Sciences as Program Supporter

ABM Industries

ABM Industries, Bristol-Myers and UGI are three examples of companies that saw earnings-per-share grow by high rates during the 2007 to 2009 period. All three companies have extensive dividend growth track records and each stock yields higher than what the S&P 500 is paying.

3 Recession-Proof Dividend Stocks to Buy

It's been a great year for Bristol-Myers Squibb this year, but it's not too late to jump in. BMY stock offers a respectable dividend.

Best Stocks for 2022: Bristol-Myers Squibb Isn't Done Growing

Regeneron Pharmaceuticals

The trend is our friend in this market, and these two biopharmaceutical stocks are trending exceptionally well.

BioPharma Giants Print Fresh All-Time Highs

The shares of Bristol-Myers Squibb Co (NYSE:BMY) have been on a steady uptrend over the last several months, while boasting low implied volatility (IV).

Red-Hot Drug Stock Has Room to Run

The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.

Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi

Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.

Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for CAR T Cell Therapy Breyanzi for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Certain Forms of Relapsed or Refractory Large B-cell Lymphoma

American Express

They're cheap buys that can be excellent recovery stocks to hold right now.

2 Buffett Stocks That Are Great Buys in April

Alnylam Pharmaceuticals

Aptinyx Inc

Blueprint Medicines

Coherus BioSciences

Hutchison China MediTech Ltd.

Tarsus Pharmaceuticals

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belonging to the sector seeing some of these make-or-break catalysts.

7 Biotech Stocks to Buy With Key Catalysts for April

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo with Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced, Recurrent....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as First-Line Treatment for Patients with.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Patients with Unresectable Advanced, Recurrent....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Receives European Commission Approval for Opdivo as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive....

Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%

Garmin

Intel

Coca-Cola

Netflix

Skyworks Solutions

Trade Desk

Start your stock scan with companies showing strong quant scores in value, growth and quality, then buy those with strong catalysts. The post 7 No-Brainer Stocks to Buy for April appeared first on InvestorPlace.

7 No-Brainer Stocks to Buy for April

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--BMS Announces New Long-Term Extension Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes....

Bristol Myers Squibb Announces Data from EXPLORER-LTE Demonstrating Sustained Improvements in Clinically Meaningful Cardiovascular Outcomes at Weeks 48 and 84 in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Receiving Mavacamten

Merck

2 Drugmakers Set for Explosive Revenue This Decade

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACC--Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Therapy in Symptomatic Obstructive HCM Patients in Phase 3 VALOR Trial

The company gives investors plenty of reasons to buy and hold the stock for years.

5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy

Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.

Bristol Myers (BMY) Application for Opdivo With Chemo Validated

Exelixis

Are these two companies solid long-term bets?

2 Stocks Defying the Market Sell-Off Right Now

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--European Medicines Agency Validates BMS's Application for Opdivo with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer

News for Bristol-Myers Stock (BMY)